Could the results of the immunogenicity mice study be delayed to coincide with the ipo of ngio?.....that is a possibility....i think it will be detrimental to come out with a 'complete vaccine' and the company is still not on the nasdaq....i mean it is registered with the sec....but not yet 'churning'.....what do you all think?...